September 11, 2024 – Talk Bio

Actionable Insights Powered by AI

GSK Abandons HSV Vaccine Development After Phase 2 Failure, Paving Way for Moderna and BioNTech

7 months ago talkbio0Tagged BioNTech, HSV vaccine, Moderna, RNA, Messenger, Simplexvirus, SmithKline Beecham

GSK, HSV vaccine, phase 2 failure, Moderna, BioNTech, mRNA vaccines, herpes simplex virus

BridgeBio Cuts Gene Therapy Budget by Over $50 Million Following Disappointing Early-Phase Data

7 months ago talkbio0Tagged BBP-631, BridgeBio, Budgets, Congenital adrenal hyperplasia, early-phase, gene therapy

BridgeBio, gene therapy, budget cut, early-phase data, CAH treatment, BBP-631, congenital adrenal hyperplasia

Gilead Sciences and Genesis Therapeutics Collaborate on AI-Driven Small Molecule Drug Discovery

7 months ago talkbio0Tagged Artificial Intelligence, Drug Development, Drug Discovery, FOXD3 gene, generative, Gilead Sciences, small molecule therapies, strategic partnership

Gilead Sciences, Genesis Therapeutics, AI-driven drug discovery, small molecule therapies, strategic partnership, generative AI, drug development

Novo Nordisk Reports Significant Weight Loss with New Dual-Acting Oral Drug in Early Clinical Trial

7 months ago talkbio0Tagged Agonist, Clinical Trials, dual-acting oral drug, Glucagon-Like Peptide-1 Receptor, Nordisk, Obesity

Novo Nordisk, weight loss, dual-acting oral drug, early clinical trial, obesity treatment, GLP-1 receptor agonist

Innovent Biologics Reports Promising Results in Early-Stage Study of Bispecific Antibody IBI363 in Lung Cancer Patients

7 months ago talkbio0Tagged Antibodies, Bispecific, Biological Factors, Early-Stage Study, IBI363, Innovent, Malignant neoplasm of lung, Non-Small Cell Lung Carcinoma, PD-1/IL-2, α-bias

Innovent Biologics, IBI363, Bispecific Antibody, Lung Cancer, Early-Stage Study, PD-1/IL-2 α-bias, Non-Small Cell Lung Cancer (NSCLC)

Bain Capital Raises $3 Billion for Fourth Life Sciences Fund to Support Innovative Biotech Startups

7 months ago talkbio0Tagged Bain Capital, biotech startups, Capital, Funds, venture

Bain Capital, Life Sciences Fund, Biotech Startups, Venture Capital, Funding

Elinzanetant Demonstrates Sustained Efficacy Over One Year in Managing Menopausal Vasomotor Symptoms

8 months ago talkbio0Tagged Bayer, Elinzanetant, Menopause, Non-Hormonal, Sleep, Symptoms aspect, Vasomotor

Elinzanetant, Menopause, Vasomotor Symptoms, Sleep Disturbances, Non-Hormonal Treatment, Bayer

Roivant Sciences Acquires Experimental Pulmonary Hypertension Drug Mosliciguat from Bayer

8 months ago talkbio0Tagged Bayer, Lung Diseases, Interstitial, Mosliciguat, PH-ILD, Pulmonary Hypertension, Pulmovant, Roivant

Roivant Sciences, Pulmovant, Bayer, Mosliciguat, Pulmonary Hypertension, PH-ILD, Interstitial Lung Disease

EASD24: Lilly’s Weekly Insulin Efsitora Demonstrates Efficacy but Raises Hypoglycemia Concerns

8 months ago talkbio0Tagged Diabetes, Diabetes Mellitus, Non-Insulin-Dependent, EASD24, efsitora, Eli, Eli Lilly, Hypoglycemia, Insulin, insulin therapy, Weekly

Eli Lilly, EASD24, Weekly Insulin, Efsitora, Type 1 Diabetes, Type 2 Diabetes, Hypoglycemia, Insulin Therapy

Centessa’s ORX750 Demonstrates Promising ‘Best-in-Class’ Profile in Early Narcolepsy Trial

8 months ago talkbio0Tagged Agonist, Centessa Pharmaceuticals, Clinical Trials, Narcolepsy, ORX750, Phase 1 (qualifier value), sleep-wake disorders

Centessa Pharmaceuticals, ORX750, narcolepsy, orexin receptor 2 agonist, sleep-wake disorders, clinical trial, Phase 1 data